36C25019Q0249.docx
DOCX document 14 KB Posted
- Solicitation number
- 36C25019Q0249
About this file
36C25019Q0249 36C25019Q0249.docx
View the file
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
36C25019Q0249- NOTICE OF INTENT TO SOLE SOURCE- BPA
FedBizOpps Special Notice
CLASSIFICATION CODE
SUBJECT
CONTRACTING OFFICE'S
ZIP-CODE
SOLICITATION NUMBER
ARCHIVE
DAYS AFTER THE RESPONSE DATE
RECOVERY ACT FUNDS
NAICS CODE
CONTRACTING OFFICE
ADDRESS
POINT OF CONTACT
(POC Information Automatically Filled from User Profile Unless Entered)
DESCRIPTION
See Attachment
AGENCY'S URL
URL DESCRIPTION
AGENCY CONTACT'S EMAIL
ADDRESS
EMAIL DESCRIPTION
GENERAL INFORMATION
ADDITIONAL INFORMATION
* = Required Field FedBizOpps Special Notice Rev. March 2010 Intent to Sole Source- BPA for Xofigo Nuclear Medicine, Cincinnati VAMC 45219 36C25019Q0249 N 325412 Department of Veterans Affairs Network Contracting Office (NCO) 10 260 E. University Avenue Cincinnati OH 45219 Ronetta Sweeney www.VA.gov Department of Veterans Affairs Ronetta.Sweeney@va.gov Ronetta Sweeney, Contracting Officer The VISN 10, Network Contracting Office (NCO 10) hereby gives notice of the Government’s intent to establish a single source blanket purchase agreement (BPA) with Cardinal Health Nuclear & Precision Health Solutions: 7000 Cardinal Place, Dublin, Ohio to acquire Xofigo (radium Ra-223 dichloride) injections, a pharmaceutical used to treat advanced prostate cancer. This BPA will be used as a simplified method of filling anticipated repetitive needs for providing Xofigo to treat patients receiving nuclear medicine services at the Cincinnati VA Medical Center: 3200 Vine Street, Cincinnati, OH, 45220. This BPA will be established IAW FAR 13.303 IAW FAR 13.106-1(b), this BPA will be established with a single source, Cardinal Health, because the original manufacturer of Xofigo, Bayer Healthcare Pharmaceuticals, has furnished documentation delegating Cardinal Health as the sole distributor for Xofigo. Additionally, Xofigo has been classified as a ‘covered drug’ under the Pharmaceutical Pricing Agreement IAW Public Law 102-585. The assigned North American Industry Classification System (NAICS) code is 325412 and the Federal Supply Code (FSC) is 6505.
Please do not request a copy of a solicitation. This notice is neither a request for competitive proposals, nor is it a solicitation of offers. Any response to this notice must demonstrate clear and convincing evidence that competition would be advantageous to the Government and any capability statement provided must address services listed above.
Written communication received will be considered informational, and may be used as market research for determining procurement methods for future contract actions. If no affirmative written response is received on or before January 7, 2018, 2:00 PM EST, the BPA will be issued without further notice. No telephone inquiries will be accepted. Inquiries will only be accepted via email at Ronetta.Sweeney@va.gov. A determination by the Government to not compete this requirement based on responses to this notice is solely within the discretion of the Government.
THIS SYNOPSIS DOES NOT COMMIT THE GOVERNMENT TO CONTRACT FOR ANY SUPPLY OR SERVICE. THE GOVERNMENT WILL NOT PAY FOR ANY INFORMATION OR ADMINISTRATIVE COSTS INCURRED IN RESPONSE TO THIS SYNOPSIS.
File details come from the government source that posted it.